Chemistry:Atilotrelvir
From HandWiki
Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19.[1][2] It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).[3]
In combination with ritonavir, it was approved for use in China in 2023.[4]
References
- ↑ "Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial". eClinicalMedicine 71. May 2024. doi:10.1016/j.eclinm.2024.102582. PMID 38618202.
- ↑ "Discovery of GST-HG171, A Potent and Selective Oral 3CL Protease Inhibitor for the Treatment of COVID-19". SM Journal of Infectious Diseases 6 (9). 2023. https://www.jsmcentral.org/sm-infectious-diseases/smjid685562.pdf.
- ↑ "Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171". Antimicrobial Agents and Chemotherapy 68 (1): e0111523. January 2024. doi:10.1128/aac.01115-23. PMID 38099673.
- ↑ "Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy 9 (1). February 2024. doi:10.1038/s41392-024-01770-y. PMID 38378623.
 |  |
